When using cabergoline for prolactinoma treatment, at what dose do you counsel patients about the risk of valvular heart disease?

I always mention the possible risk of cardiac valvulopathy when prescribing cabergoline. However, I also mention that the studies showing evidence of possible harm were in patients with Parkinson's disease who were taking much higher doses than those prescribed for typical hyperprolactinemic patient...